KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Net Income towards Common Stockholders fell 21719.61% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 13194.75%. This contributed to the annual value of $73.9 million for FY2024, which is 551284.19% up from last year.
  • Supernus Pharmaceuticals' Net Income towards Common Stockholders amounted to -$45.1 million in Q3 2025, which was down 21719.61% from $22.5 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Net Income towards Common Stockholders registered a high of $38.5 million during Q3 2024, and its lowest value of -$45.1 million during Q3 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $7.8 million (2022), whereas its average is $8.1 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 250652.96% in 2024, then plummeted by 964112.9% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then plummeted by 95.39% to $1.2 million in 2023, then skyrocketed by 1208.68% to $15.4 million in 2024, then tumbled by 393.41% to -$45.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$45.1 million for Q3 2025, versus $22.5 million for Q2 2025 and -$11.8 million for Q1 2025.